Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01804686 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Study acronym: CAN3001
StatusRecruiting
PhasePhase 3
Started2013-09-09
View on ClinicalTrials.gov ↗
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Amendment history 3 changes detected by DataLookout

2026-08-01
Completion moved earlier: 2030-12-31 → 2029-12-31
2026-07-08
Completion pushed: 2029-12-31 → 2030-12-31
2026-06-06
Completion pushed: 2027-08-31 → 2029-12-31
Trial Details
NCT Number NCT01804686
Lead Sponsor Janssen Research & Development, LLC
Collaborators: Pharmacyclics LLC.
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Enrollment 700 participants
Start Date 2013-09-09
Primary Completion 2026-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31